Gilead (Kite)
Public GILD · United States
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
15 approved
11 in Phase 3
Drugs
51
in active trials · 117 in all
Trials
89 active
263 since 2021
Drugs51
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
TROP2-targeted antibody-drug conjugate |
Approved | Dec 2026Phase 3 trial completes | |||
| Next date | Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Triple Negative Breast Cancer, Metastatic Breast Cancer and 21 more | ||||
| Open drug page | |||||
Human immunodeficiency virus 1 capsid inhibitor |
Approved | Mar 2027Phase 2 trial completes | |||
| Next date | Mar 2027 · Phase 2 trial completes | ||||
| Also tested for | HIV-1-infection, Pre-Exposure Prophylaxis of HIV Infection and 3 more | ||||
| Open drug page | |||||
— |
Approved | Jun 2027Phase 4 trial completes | |||
| Next date | Jun 2027 · Phase 4 trial completes | ||||
| Also tested for | HIV-1-infection, HIV-1 Infection | ||||
| Open drug page | |||||
Cytochrome P450 3A inhibitor |
Approved | Jun 2027Phase 4 trial completes | |||
| Next date | Jun 2027 · Phase 4 trial completes | ||||
| Also tested for | Acquired Immune Deficiency Syndrome (AIDS), HIV Infections and 1 more | ||||
| Open drug page | |||||
— |
Approved | Jun 2027Phase 4 trial completes | |||
| Next date | Jun 2027 · Phase 4 trial completes | ||||
| Also tested for | HIV-1-infection | ||||
| Open drug page | |||||
— |
Approved | Jun 2027Phase 4 trial completes | |||
| Next date | Jun 2027 · Phase 4 trial completes | ||||
| Also tested for | Pre-Exposure Prophylaxis of HIV Infection, Acquired Immune Deficiency Syndrome (AIDS) and 2 more | ||||
| Open drug page | |||||
Gene therapy substances |
Approved | Jul 2027Phase 2 trial completes | |||
| How it works | A gene therapy | ||||
| Next date | Jul 2027 · Phase 2 trial completes | ||||
| Also tested for | Relapsed/Refractory Mantle Cell Lymphoma, Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | ||||
| Open drug page | |||||
Bruton's tyrosine kinase inhibitor |
Ono Pharmaceutical |
Approved in Japan | 30 Sep 2027Phase 3 trial completes | ||
| How it works | Blocks BTK | ||||
| Next date | 30 Sep 2027 · Phase 3 trial completes | ||||
| Also tested for | Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma and 4 more | ||||
| Open drug page | |||||
— |
Approved | Jul 2028Phase 4 trial completes | |||
| Next date | Jul 2028 · Phase 4 trial completes | ||||
| Also tested for | HIV-1-infection, HIV-1 Infection | ||||
| Open drug page | |||||
— |
Approved | Nov 2028Phase 3 trial completes | |||
| Next date | Nov 2028 · Phase 3 trial completes | ||||
| Also tested for | Primary Biliary Cholangitis, Primary Biliary Cirrhosis | ||||
| Open drug page | |||||
Gene therapy substances |
Approved | Oct 2030Phase 3 trial completes | |||
| How it works | A gene therapy | ||||
| Next date | Oct 2030 · Phase 3 trial completes | ||||
| Also tested for | Relapsed/Refractory Follicular Lymphoma, High-risk Large B-cell Lymphoma (LBCL) and 1 more | ||||
| Open drug page | |||||
— |
Approved | — | |||
| Also tested for | HIV-1-infection | ||||
| Open drug page | |||||
— |
Approved | — | |||
| Also tested for | Pre-Exposure Prophylaxis of HIV Infection | ||||
| Open drug page | |||||
Tenofovir Alafenamidenot checked |
Hepatitis B virus nucleoside analog reverse transcriptase Inhibitor; human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor |
Approved | — | ||
| Also tested for | Chronic Hepatitis B | ||||
| Open drug page | |||||
— |
Approved | — | |||
| Also tested for | Chronic Hepatitis B | ||||
| Open drug page | |||||
Gene therapy substances |
Phase 3 | Dec 2026Phase 2 trial completes | |||
| How it works | A gene therapy | ||||
| Next date | Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Multiple Myeloma, Newly Diagnosed Multiple Myeloma and 8 more | ||||
| Open drug page | |||||
TIGIT antibody |
Arcus Biosciences |
Phase 3 | Mar 2027Phase 2 trial completes | ||
| Next date | Mar 2027 · Phase 2 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Metastatic Urothelial Cancer and 5 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 3 | Mar 2027Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | Mar 2027 · Phase 2 trial completes | ||||
| Also tested for | Metastatic Urothelial Cancer, Advanced Solid Tumor and 9 more | ||||
| Open drug page | |||||
— |
Phase 2/3 | Aug 2027Phase 2 trial completes | |||
| Next date | Aug 2027 · Phase 2 trial completes | ||||
| Also tested for | HIV-1-infection, HIV-1 Infection | ||||
| Open drug page | |||||
— |
Phase 2/3 | Jan 2028Phase 2/3 trial completes | |||
| Next date | Jan 2028 · Phase 2/3 trial completes | ||||
| Also tested for | HIV-1-Infection | ||||
| Open drug page | |||||
No drugs match “”.
SEC filings32
Since Feb 2024 · All on SEC.gov- 29 OctReported quarterly results · SEC 8-K
- 4 AugReported quarterly results · SEC 8-K
- 20 MaySigned a material agreement, took on new debt and reported other events · SEC 8-K
- 14–18 MayOffered new securities · 2 prospectuses (424B5)
- 7 MayReported quarterly results · SEC 8-K
- 4 MayFiled a report · SEC 8-K
- 28 AprMade a public disclosure and reported other events · SEC 8-K
- 23 FebSigned a material agreement and made a public disclosure · SEC 8-K
- 10 FebReported quarterly results · SEC 8-K
- 19 Nov 2025Changed a director or officer · SEC 8-K
- 30 Oct 2025Reported quarterly results · SEC 8-K
- 6 Oct 2025Made a public disclosure · SEC 8-K
- 14 Aug 2025Changed a director or officer · SEC 8-K
- 7 Aug 2025Reported quarterly results · SEC 8-K
- 4 Aug 2025Filed a report · SEC 8-K
- 8 May 2025Filed a report · SEC 8-K
- 24 Apr 2025Reported quarterly results · SEC 8-K
- 12 Mar 2025Changed a director or officer · SEC 8-K
- 11 Feb 2025Reported quarterly results · SEC 8-K
- 13 Dec 2024Changed a director or officer · SEC 8-K
- 20 Nov 2024Signed a material agreement, took on new debt and reported other events · SEC 8-K
- 13–15 Nov 2024Offered new securities · 2 prospectuses (424B5)
- 6 Nov 2024Reported quarterly results · SEC 8-K
- 8 Aug 2024Reported quarterly results · SEC 8-K
- 17 Jul 2024Changed a director or officer · SEC 8-K
- 9 May 2024Filed a report · SEC 8-K
- 25 Apr 2024Reported quarterly results · SEC 8-K
- 22 Mar 2024Made a public disclosure and reported other events · SEC 8-K
- 14 Mar 2024Changed a director or officer · SEC 8-K
- 12 Feb 2024Signed a material agreement and reported other events · SEC 8-K
- 6 Feb 2024Reported quarterly results · SEC 8-K
- 2 Feb 2024Changed a director or officer · SEC 8-K
About
- No active trial
- 66 other drugs
- Registry names
- 2 names in ClinicalTrials.gov Gilead Sciences
Kite, A Gilead Company - Sources
- ClinicalTrials.gov updated 16 Nov 2026 · SEC filings Industry-sponsored drug trials since 2021 · Logos provided by Logo.dev